SBP successfully sells Rs63.8bn in Market Treasury Bills

Out of a total amount offered, the SBP accepted Rs64 billion, reflecting a strong market response.

In a recent auction on Tuesday, the State Bank of Pakistan (SBP) achieved a notable success by selling Market Treasury Bills (MTBs) worth Rs63.84 billion for durations of 3, 6, and 12 months. Despite a target set at Rs480 billion, the SBP efficiently managed to secure substantial bids.

The cut-off yields for the respective periods stood at 20.4399%, 20.3951%, and 20.0800%. There was a significant decline of 6 basis points (bps) and 15 bps in the 3-month and 12-month categories, while the yield for the 6-month papers remained stable.

Out of a total amount offered, the SBP accepted Rs64 billion, reflecting a strong market response. The bids received were Rs482.66 billion for 3 months, Rs80.29 billion for 6 months, and Rs589.88 billion for 12 months. The SBP accepted Rs17.53 billion for 3 months and Rs5 billion for 12 months from the respective categories.

Furthermore, the SBP acquired Rs41.31 billion from the non-competitive auction, contributing to the total accepted amount of Rs64 billion. The bid-to-cover ratio, illustrating the ratio of bids received to the amount sold, experienced a significant rise, reaching 18.06 compared to 6.24 in the previous auction. In essence, the SBP accepted approximately 5.54% of the total bids received.

In the last auction on January 10, 2024, the SBP sold MTBs worth Rs185 billion against a target of Rs225 billion, with cut-off yields of 20.4997%, 20.4%, and 20.2298% for 3, 6, and 12 months, respectively. The recent success reflects the continued confidence of investors in the financial instruments offered by the State Bank of Pakistan.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Must Read

Lucky Core seals deal for Pfizer’s Karachi plant, pharma products

Asset Purchase Agreements signed, acquisition includes products such as Ansaid, Ponstan, Ponstan Forte, Basoquin, Deltacortril, Lysovit, Corex-D, and Mycitracin.Â